Sana Biotechnology, Inc. (NASDAQ:SANA) Shares Sold by Crestline Management LP

Crestline Management LP decreased its position in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) by 7.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,860,937 shares of the company’s stock after selling 224,687 shares during the period. Crestline Management LP owned 1.28% of Sana Biotechnology worth $4,663,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the company. Brevan Howard Capital Management LP purchased a new stake in Sana Biotechnology in the 4th quarter valued at $120,000. Bank of America Corp DE raised its holdings in shares of Sana Biotechnology by 11.3% in the fourth quarter. Bank of America Corp DE now owns 1,131,813 shares of the company’s stock valued at $1,845,000 after buying an additional 115,347 shares during the last quarter. BNP Paribas Financial Markets acquired a new stake in shares of Sana Biotechnology during the fourth quarter worth about $34,000. Ameriprise Financial Inc. purchased a new position in shares of Sana Biotechnology during the fourth quarter worth about $29,000. Finally, Boxer Capital Management LLC purchased a new stake in Sana Biotechnology during the 4th quarter valued at approximately $2,518,000. 88.23% of the stock is owned by institutional investors and hedge funds.

Sana Biotechnology Trading Down 8.6 %

Shares of SANA opened at $1.71 on Wednesday. The firm’s 50-day moving average is $1.98 and its two-hundred day moving average is $2.52. Sana Biotechnology, Inc. has a twelve month low of $1.26 and a twelve month high of $10.23. The firm has a market capitalization of $385.57 million, a P/E ratio of -1.22 and a beta of 1.75.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings data on Monday, March 17th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.02. Analysts predict that Sana Biotechnology, Inc. will post -1.16 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on SANA shares. Jefferies Financial Group began coverage on Sana Biotechnology in a report on Friday, March 14th. They issued a “buy” rating and a $7.00 target price on the stock. Citizens Jmp upgraded shares of Sana Biotechnology from a “market perform” rating to an “outperform” rating and set a $5.00 target price for the company in a research note on Tuesday, March 18th. TD Cowen upgraded shares of Sana Biotechnology from a “hold” rating to a “buy” rating in a research note on Wednesday, January 8th. Finally, HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of Sana Biotechnology in a research report on Thursday, April 24th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, Sana Biotechnology currently has a consensus rating of “Moderate Buy” and an average target price of $10.80.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.